Last updated: February 13, 2026
Overview
NDC 00143-1171 refers to a branded formulation of cisplatin, a platinum-based chemotherapy drug used primarily to treat various cancers, including lung, ovarian, bladder, and testicular cancers. The drug is administered intravenously and has been available for decades, with multiple generic versions entering the market.
Market Size and Dynamics
The global oncology drug market was valued at approximately USD 160 billion in 2022[1], with chemotherapy agents representing a significant segment. Cisplatin remains a staple in oncological protocols due to its efficacy, though it faces competition from newer agents and targeted therapies.
Key drivers for cisplatin include:
- High clinical adoption: Widely used in combination therapies.
- Patent expiries: Generic versions increase price competition.
- Expanding indications: Ongoing trials suggest potential new uses.
Market dynamics are influenced by patent statuses, regulatory environments, hospital formularies, and the pace of pharmaceutical innovation.
Pricing Landscape
Historical pricing of cisplatin has experienced fluctuations based on formulation, manufacturing costs, and market competition. In the United States, the average wholesale price (AWP) for a 50 mg vial of branded cisplatin was approximately USD 100-150 in 2022, while generics are priced at about USD 20-50 per vial. Price reductions are common with increased generic penetration.
Pricing Trends
| Year |
Average Price of Branded Cisplatin (USD per vial) |
Average Price of Generic Cisplatin (USD per vial) |
| 2018 |
150 |
25 |
| 2019 |
135 |
22 |
| 2020 |
125 |
20 |
| 2021 |
120 |
18 |
| 2022 |
120 |
15-20 |
Price projections suggest further declines driven by competitive generic manufacturing and biosimilar development. However, because of manufacturing costs and market segmentation, branded formulations may sustain higher prices in niche markets or for specific indications.
Future Price Projections (2023–2027)
- Base Case: Generic prices stabilize around USD 10–20 per vial, with minimal fluctuation.
- Upside Scenario: New formulations with reduced toxicity or enhanced delivery efficiencies emerge, allowing premium pricing to be maintained, reaching USD 25–30 per vial.
- Downside Scenario: Further fragmentation of the market with increased generics and biosimilars drives prices toward USD 5–10 per vial.
Regulatory and Market Factors Influencing Price
- Patent Expirations: Patent for branded cisplatin expired in most markets by the late 2000s, leading to generic proliferation.
- Regulatory Approvals: New indications or formulations require extensive clinical trials and regulatory review, potentially impacting pricing.
- Reimbursement Policies: Insurance coverage and hospital procurement policies influence the actual prices paid.
- Competitive Innovations: Development of carboplatin and oxaliplatin offers competitors to cisplatin, affecting market share and pricing.
Challenges in Market Forecasting
- Variability in regional regulations impacts price and availability.
- Shifts toward oral or targeted therapies may reduce cisplatin utilization.
- Supply chain disruptions could alter manufacturing costs and prices.
Summary
Cisplatin (NDC 00143-1171) continues to be a cost-effective, extensively used chemotherapy agent. Market prices are expected to remain low due to generic competition, with slight potential for premium pricing if new formulations or indications are approved.
Key Takeaways
- The overall market for cisplatin remains mature with declining prices, primarily driven by generic competition.
- Current wholesale prices are likely to stay within USD 10-20 per vial in the next 3–5 years.
- Innovator brands may maintain marginally higher prices for specialized indications or formulations.
- Market concerns include competition from newer platinum compounds and targeted therapies.
- Price margins are squeezed further by transparent pricing and institutional purchasing.
FAQs
1. How does generic entry influence cisplatin pricing?
Generic entry significantly lowers prices, with market prices often dropping by 70–80% within a few years after patent expiration.
2. Are there regional differences in cisplatin pricing?
Yes. Prices vary across countries due to regulatory policies, reimbursement schemes, and market competition. For example, prices in Europe are often higher than in the US or emerging markets.
3. What is the impact of new formulations on market prices?
Innovative formulations that reduce toxicity or improve efficacy can command higher prices but may slow down overall price declines for existing formulations.
4. What emerging therapies could threaten cisplatin's market share?
Targeted therapies and immunotherapies offer alternatives for certain cancers, potentially reducing reliance on cisplatin in treatment protocols.
5. When might prices for cisplatin increase again?
Only if supply chain issues, regulatory changes, or significant new indications emerge that limit generic competition or justify premium pricing.
Citations
[1] IQVIA, "Global Oncology Market Summary," 2022.
